Harry D. Bear

General Surgery

1250 E Marshall St
Richmond, VA 23298

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

DNA Methyltransferase Inhibitors, Decitabine and Guadecitabine Overcome Immune-Checkpoint Blockade Resistance and Achieve Tumor Regression in the E0771 and 4T1 Murine Models of Triple-Negative Breast Cancer.

DNA Methyltransferase Inhibitors, Decitabine and Guadecitabine Overcome Immune-Checkpoint Blockade Resistance and Achieve Tumor Regression in the E0771 and 4T1 Murine Models of Triple-Negative Breast Cancer.

Journal: Cancers

Published: June 22, 2026

Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time - A TriNetX Database Study.

Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time - A TriNetX Database Study.

Journal: Clinical breast cancer

Published: March 09, 2026

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: November 05, 2025

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Journal: JCO precision oncology

Published: September 02, 2025

Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?

Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: September 01, 2025

Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis.

Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis.

Journal: British journal of cancer

Published: August 28, 2025

Allostatic Load and Racial and Rural Disparities in Breast Cancer Survival.

Allostatic Load and Racial and Rural Disparities in Breast Cancer Survival.

Journal: JAMA network open

Published: August 21, 2025

Correction: Shen et al. Neighborhood Disadvantage, Built Environment, and Breast Cancer Outcomes: Disparities in Tumor Aggressiveness and Survival. Cancers 2025, 17, 1502.

Correction: Shen et al. Neighborhood Disadvantage, Built Environment, and Breast Cancer Outcomes: Disparities in Tumor Aggressiveness and Survival. Cancers 2025, 17, 1502.

Journal: Cancers

Published: June 12, 2025

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

Journal: JCO precision oncology

Published: April 10, 2025

Neighborhood Disadvantage, Built Environment, and Breast Cancer Outcomes: Disparities in Tumor Aggressiveness and Survival.

Neighborhood Disadvantage, Built Environment, and Breast Cancer Outcomes: Disparities in Tumor Aggressiveness and Survival.

Journal: Cancers

Published: March 17, 2025

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.

Journal: Journal for immunotherapy of cancer

Published: February 12, 2025

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 03, 2025

Showing 1-12 of 77

Last Updated: 09/26/2026